| Literature DB >> 25428571 |
Valerie C Brueton, Claire L Vale1, Babak Choodari-Oskooei, Rachel Jinks, Jayne F Tierney.
Abstract
BACKGROUND: Providing evidence of impact highlights the benefits of medical research to society. Such evidence is increasingly requested by research funders and commonly relies on citation analysis. However, other indicators may be more informative. Although frameworks to demonstrate the impact of clinical research have been reported, no complementary framework exists for methodological research. Therefore, we assessed the impact of methodological research projects conducted or completed between 2009 and 2012 at the UK Medical Research Council Clinical Trials Unit Hub for Trials Methodology Research Hub, with a view to developing an appropriate framework.Entities:
Mesh:
Year: 2014 PMID: 25428571 PMCID: PMC4258950 DOI: 10.1186/1745-6215-15-464
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Figure 1Journals in which MRC CTU methodology papers were most frequently published, 2009 to 2012 (top 63% of all articles).
Figure 2Journal types publishing MRC CTU Hub methodology papers (2009 to 2012).
Figure 3Average number of citations per publication per year (2009 to 2013).
Methodology projects
| Project title | Methodology area | Interviewee number* |
|---|---|---|
| Flexible parametric models | Statistical | 13 |
| Missing data for prognostics | Statistical | 13 |
| Multi-variable modelling, prognostic modelling | Statistical | 13 |
| Modelling the association between patient characteristics and change over time in a disease measure | Statistical | 3 |
| Combining multiple imputation and inverse probability weighting | Statistical | 3 |
| New measure of the predictive ability for a survival model | Statistical | 7 |
| Bias two-arm multi-stage trials | Statistical | 7 |
| Analysis of resources for trials | Statistical | 8 |
| Restricted mean survival time | Statistical | 4 |
| Multi-arm multi-stage trial design | Statistical | 5, 10 |
| Biomarkers | Statistical | 4 |
| Comparing dynamic treatment regimens or monitoring strategies | Statistical | 11, 12 |
| Estimating the effect of time-varying treatment or exposure on outcome | Statistical | 11, 12 |
| Developing guidance for researchers on patient and public involvement in clinical research | Trial conduct | 2 |
| Consumer involvement in MRC CTU studies | Trial conduct | 2 |
| DAMOCLES (DAta MOnitoring Committees: Lessons, Ethics, Statistics) | Trial conduct | 5 |
| Retention strategies for randomized trials | Trial conduct | 14 |
| Central monitoring techniques to replace on-site monitoring | Trial conduct | 6 |
| Risk-based monitoring of trials | Trial conduct | 9 |
| Analysis of subgroup interactions in individual patient data meta-analysis | Meta-analysis | 1 |
|
| 20 | 14 |
*Interviewees 2, 3, 4, 5, 7, 11, 12 and 13 discussed more than one project. CTU, clinical trials unit; MRC, UK Medical Research Council.
Research outputs identified through interviews
| Research output | Total | Range per project | Median per project |
|---|---|---|---|
| Meetings | 1 | — | — |
| Workshops | 10 | 1 to 3 | 1 |
| Lectures | 32 | 1 to 10 | 2 |
| Conference presentations | 42 | 1 to 18 | 2 |
Figure 4Impacts for the MRC CTU Hub multi-arm multi-stage trial design 2009 to 2012. *Publications from 2008 to 2013 only.